Covid-19 roundup: Shionogi’s antiviral pill hits the mark; Ocugen strikes deal for intranasal vaccine
Japanese pharma Shionogi’s Covid-19 antiviral against Omicron passed its Phase III trial in Asia, meeting its primary endpoint.
The drug, a protease inhibitor known as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
